Literature DB >> 26781864

[Vitiligo: Clinical presentation and pathogenesis].

M Schild1, M Meurer2.   

Abstract

BACKGROUND: Vitiligo is a chronic skin disorder with depigmentation of circumscribed areas due to structural and functional damage to melanocytes.
RESULTS: There is international consensus on the classification in nonsegmental and segmental vitiligo. The influence of vitiligo on the quality of life is significant and is influenced by ethnic and sociocultural factors. There is a new insight into the genetic susceptibility, mechanisms and targets of the autoimmune inflammation, the altered morphology and function of melanocytes and into the association of vitiligo with other autoimmune diseases, skin cancer and skin cancer therapy.
CONCLUSIONS: The recognition of associated autoimmune disorders is as important as is the assessment of changes in the quality of life. New insight into the pathogenesis may have therapeutic consequences. The relationship between vitiligo and skin cancer and between vitiligo and immunotherapies in patients with metastatic melanoma warrants close clinical monitoring of affected patients and further scientific studies.

Entities:  

Keywords:  Autoimmune diseases; Diagnostic workup; Differential diagnoses; Quality of life; Skin cancer

Mesh:

Year:  2016        PMID: 26781864     DOI: 10.1007/s00105-015-3751-5

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  79 in total

1.  The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force.

Authors:  Alain Taïeb; Mauro Picardo
Journal:  Pigment Cell Res       Date:  2007-02

2.  Guidelines for the management of vitiligo: the European Dermatology Forum consensus.

Authors:  A Taieb; A Alomar; M Böhm; M L Dell'anna; A De Pase; V Eleftheriadou; K Ezzedine; Y Gauthier; D J Gawkrodger; T Jouary; G Leone; S Moretti; L Nieuweboer-Krobotova; M J Olsson; D Parsad; T Passeron; A Tanew; W van der Veen; N van Geel; M Whitton; A Wolkerstorfer; M Picardo
Journal:  Br J Dermatol       Date:  2012-11-02       Impact factor: 9.302

3.  Immunohistochemical evaluation of vitiliginous hair follicle melanocyte reservoir: is it retained?

Authors:  I Seleit; O A Bakry; A G Abdou; N M Dawoud
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-06-09       Impact factor: 6.166

4.  Relevance of autoimmune thyroiditis in children and adolescents with vitiligo.

Authors:  Sibel Uncu; Savaş Yaylı; Sevgi Bahadır; Ayşenur Okten; Köksal Alpay
Journal:  Int J Dermatol       Date:  2011-02       Impact factor: 2.736

5.  Evidence that the bulge region is a site of relative immune privilege in human hair follicles.

Authors:  K C Meyer; J E Klatte; H V Dinh; M J Harries; K Reithmayer; W Meyer; R Sinclair; R Paus
Journal:  Br J Dermatol       Date:  2008-09-15       Impact factor: 9.302

6.  Incidence of nonmelanoma skin cancer in a cohort of patients with vitiligo.

Authors:  Camile L Hexsel; Melody J Eide; Christine C Johnson; Richard Krajenta; Gordon Jacobsen; Iltefat Hamzavi; Henry W Lim
Journal:  J Am Acad Dermatol       Date:  2009-04-17       Impact factor: 11.527

7.  Enhanced DNA binding capacity on up-regulated epidermal wild-type p53 in vitiligo by H2O2-mediated oxidation: a possible repair mechanism for DNA damage.

Authors:  Mohamed M A E L Salem; Mohammad Shalbaf; Nicholas C J Gibbons; Bhaven Chavan; J M Thornton; Karin U Schallreuter
Journal:  FASEB J       Date:  2009-07-29       Impact factor: 5.191

8.  Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo.

Authors:  Andrea Paradisi; Stefano Tabolli; Biagio Didona; Luciano Sobrino; Nicoletta Russo; Damiano Abeni
Journal:  J Am Acad Dermatol       Date:  2014-09-19       Impact factor: 11.527

9.  Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells.

Authors:  J Cui; J C Bystryn
Journal:  Arch Dermatol       Date:  1995-03

10.  CD8+ T cells from vitiligo perilesional margins induce autologous melanocyte apoptosis.

Authors:  Jilong Wu; Miaoni Zhou; Yinsheng Wan; Aie Xu
Journal:  Mol Med Rep       Date:  2012-10-08       Impact factor: 2.952

View more
  2 in total

1.  [Treatment of vitiligo].

Authors:  M Meurer; M Schild
Journal:  Hautarzt       Date:  2016-03       Impact factor: 0.751

Review 2.  [Systemic treatment of vitiligo : Balance and current developments].

Authors:  M Meurer; P Ceric-Dehdari
Journal:  Hautarzt       Date:  2017-11       Impact factor: 0.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.